Holen Sie sich die Stockscreener-App
8.495
0.72%
0.135
Schlusskurs vom Vortag:
$8.36
Offen:
$8.4
24-Stunden-Volumen:
19,988
Relative Volume:
0.04
Marktkapitalisierung:
$149.03M
Einnahmen:
$1.54M
Nettoeinkommen (Verlust:
$-38.70M
KGV:
-1.8191
EPS:
-4.67
Netto-Cashflow:
$-36.86M
1W Leistung:
+6.99%
1M Leistung:
-16.63%
6M Leistung:
+0.60%
1J Leistung:
-32.32%
1-Tages-Spanne:
$8.3098
$8.57
1-Wochen-Bereich:
$7.63
$8.63
52-Wochen-Spanne:
$4.64
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Firmenname
Corbus Pharmaceuticals Holdings Inc
Sektor
Branche
Telefon
617-963-0103
Adresse
500 RIVER RIDGE DRIVE, NORWOOD, MA
Vergleichen Sie CRBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
8.49 | 146.74M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.36 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
811.17 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.74 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
811.36 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.32 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Eingeleitet | Wedbush | Outperform |
| 2024-07-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-06-03 | Bestätigt | Oppenheimer | Outperform |
| 2024-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-06 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-08 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2020-09-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-07 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-03-26 | Eingeleitet | Nomura | Buy |
| 2019-04-05 | Eingeleitet | Jefferies | Buy |
| 2019-03-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-01-11 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-10-24 | Eingeleitet | B. Riley FBR | Buy |
| 2018-01-19 | Eingeleitet | Raymond James | Outperform |
| 2017-12-14 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-11-08 | Bestätigt | Noble Financial | Buy |
| 2017-09-29 | Fortgesetzt | Noble Financial | Buy |
| 2017-03-30 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-11 | Bestätigt | Noble Financial | Buy |
Alle ansehen
Corbus Pharmaceuticals Holdings Inc Aktie (CRBP) Neueste Nachrichten
Why Corbus Pharmaceuticals Holdings Inc. stock could outperform in 2025Gap Up & Weekly Top Performers Watchlists - ulpravda.ru
Will Corbus Pharmaceuticals Holdings Inc. stock continue upward momentumMarket Trend Review & Weekly Top Gainers Trade List - ulpravda.ru
Will Corbus Pharmaceuticals Holdings Inc. (3371) stock sustain dividend payoutsJuly 2025 Retail & Free Verified High Yield Trade Plans - ulpravda.ru
Aug Outlook: Will Corbus Pharmaceuticals Holdings Inc. stock continue upward momentum - ulpravda.ru
Corbus Pharmaceuticals to Present Corporate Overview at the 2026 Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
While hedge funds own 24% of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), retail investors are its largest shareholders with 46% ownership - Yahoo Finance
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
How Corbus Pharmaceuticals Holdings Inc. (CRBP) Affects Rotational Strategy Timing - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals shares rise on encouraging safety results for experimental obesity drug - MSN
Downgrade Watch: Will Corbus Pharmaceuticals Holdings Inc 3371 stock top growth indexesMarket Growth Summary & Daily Volume Surge Trade Alerts - moha.gov.vn
Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Cross Below Fifty Day Moving AverageShould You Sell? - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals announces retirement of board member Holmer - MSN
Can Corbus Pharmaceuticals Holdings Inc. stock sustain institutional interest2025 EndofYear Setup & Fast Exit and Entry Trade Guides - DonanımHaber
Will Corbus Pharmaceuticals Holdings Inc. stock outperform growth indexesQuarterly Trade Review & Growth-Oriented Investment Plans - DonanımHaber
Will Corbus Pharmaceuticals Holdings Inc. stock outperform value stocksJuly 2025 Drop Watch & Consistent Return Strategy Ideas - DonanımHaber
Can Corbus Pharmaceuticals Holdings Inc. stock continue upward trendJuly 2025 PreEarnings & Free Reliable Trade Execution Plans - DonanımHaber
Corbus Pharmaceuticals Announces Retirement of Board Member Holmer - The Globe and Mail
How resilient is Corbus Pharmaceuticals Holdings Inc. stock in market downturnsJuly 2025 Sector Moves & AI Based Trade Execution Alerts - Улправда
Will Corbus Pharmaceuticals Holdings Inc. stock return to pre crisis levelsJuly 2025 Update & Entry and Exit Point Strategies - Улправда
Volume Report: How resilient is Corbus Pharmaceuticals Holdings Inc. stock in market downturnsPortfolio Gains Report & Growth Oriented Trade Recommendations - ulpravda.ru
Cormorant Asset Management, LP Reduces Stake in Corbus Pharmaceu - GuruFocus
Corbus Pharmaceuticals (CRBP) director Alan Holmer resigns from board to retire - Stock Titan
Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Alan Holmer from its Board of Directors, Effective December 31, 2025 - marketscreener.com
Rally Mode: How resilient is Corbus Pharmaceuticals Holdings Inc. stock in market downturnsJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - Улправда
Corbus Pharmaceuticals Holdings Inc. Stock Slides 8.6%, Underperforms Peers - 富途牛牛
Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Wednesday When Compared To Competitors - 富途牛牛
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Cormorant Asset Management, Lp Sells 30,029 Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) Stock - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals (CRBP) insider reports 30,029-share stock sale - Stock Titan
Discipline and Rules-Based Execution in CRBP Response - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. (CRBP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CRBP stock surged 36% pre-market – what did its obesity treatment drug study reveal? - MSN
Corbus Pharmaceuticals (CRBP) Reports Phase 1 Study Results for Obesity Drug - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus declines following early-stage results on oral obesity asset CRB-913 (CRBP:NASDAQ) - Seeking Alpha
CRBP Stock Surged 36% Pre-Market – What Did Its Obesity Treatment Drug Study Reveal? - Stocktwits
CRBP: Corbus Pharmaceuticals' Promising Phase I Study Sparks Int - GuruFocus
CRBP: CRB-913 induced rapid, significant weight loss with minimal side effects in early obesity trials - TradingView — Track All Markets
Corbus Pharmaceuticals Reports Phase 1a Obesity Drug Data Showing Weight Loss - marketscreener.com
Corbus reports positive phase 1 results for obesity drug CRB-913 - Investing.com
Corbus Pharmaceuticals Advances Obesity Treatment with CRB-913 - TipRanks
Corbus Pharmaceuticals Reports Results From Phase 1A Study Of Oral CB1 Inverse Agonist CRB-913 For The Treatment For Obesity Demonstrating Favorable Safety Profile And Emerging Evidence Of Weight Loss - TradingView — Track All Markets
Corbus Pharmaceuticals (CRBP) Advances Obesity Treatment with CR - GuruFocus
Corbus Pharmaceuticals Announces Phase 1a Study Results of CRB-913 - TradingView — Track All Markets
Corbus Pharmaceuticals stock rises after promising obesity drug safety data By Investing.com - Investing.com UK
Finanzdaten der Corbus Pharmaceuticals Holdings Inc-Aktie (CRBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Corbus Pharmaceuticals Holdings Inc-Aktie (CRBP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cohen Yuval | Chief Executive Officer |
Oct 24 '25 |
Option Exercise |
4.26 |
18,660 |
79,492 |
156,847 |
| Cohen Yuval | Chief Executive Officer |
Oct 27 '25 |
Option Exercise |
4.26 |
8,973 |
38,225 |
147,160 |
| Cohen Yuval | Chief Executive Officer |
Oct 24 '25 |
Sale |
17.01 |
18,660 |
317,407 |
138,187 |
| Cohen Yuval | Chief Executive Officer |
Oct 27 '25 |
Sale |
17.14 |
8,973 |
153,797 |
138,187 |
| Moran Sean F. | Chief Financial Officer |
Oct 24 '25 |
Option Exercise |
4.26 |
12,981 |
55,299 |
86,294 |
| Moran Sean F. | Chief Financial Officer |
Oct 24 '25 |
Sale |
17.02 |
12,981 |
220,937 |
73,313 |
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):